ReviewKidney international reports2024
Biomarkers of Kidney Disease Progression in ADPKD.
Review in Kidney international reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Serum and urine prognostic biomarkers for autosomal dominant polycystic kidney disease: a systematic review and meta-analysis.BMC nephrology · 2026Pooled it
- Beyond Sequencing: Integrating MLPA Reveals Hidden StructuralMedicina (Kaunas, Lithuania) · 2026Article
- From cystogenesis to carcinogenesis in ADPKD: risk modeling and a multistep precision surveillance.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- A pilot study of magnetic resonance fingerprinting and radiomics analysis in autosomal dominant polycystic kidney disease.Kidney international · 2026Article
- Heart-Type Fatty Acid-Binding Protein as a Marker of Subclinical Cardiac Dysfunction and Cardiorenal Interaction in Autosomal Dominant Polycystic Kidney Disease.Life (Basel, Switzerland) · 2026Article
- The Relationship of Osmolality and Kidney Outcomes in Patients with Autosomal Dominant Polycystic Kidney Disease.Kidney360 · 2026Article
- Association of 24-hour urinary parameters with renal function and other comorbidities in autosomal dominant polycystic kidney disease.BMC nephrology · 2026Article
- Evolution of Clinical Trial Design in ADPKD.Kidney international reports · 2026Review
- Glycolytic alterations as biomarkers in polycystic kidney disease: A study using a PKD1 knockout model in NRK-52E rat kidney epithelial cells.Physiological reports · 2026Article
- Canadian Society of Nephrology Commentary on the 2025 Kidney Disease Improving Global Outcomes Clinical Practice Guidelines for Autosomal Dominant Polycystic Kidney Disease.Canadian journal of kidney health and disease · 2026Article
- Characterization of Kidney and Liver Cystic Phenotype Associated with GANAB Using Advanced Imaging Biomarkers.Nephron · 2026Article
- Kidney stones and autosomal dominant polycystic kidney disease: a state-of-the-art review.Renal failure · 2025Review
- Autosomal dominant polycystic kidney disease: an overview of recent genetic and clinical advances.Renal failure · 2025Review
- Cardiovascular Autonomic Control in Normotensive Patients with Autosomal Dominant Polycystic Kidney Disease.Kidney360 · 2025Article
- Estimation of Kidney Volumes in Autosomal Dominant Polycystic Kidney Disease: A Comparison Between Manual Segmentation and Ellipsoid Formula.Clinics and practice · 2025Article
- Polycystic Kidney Disease in Children: The Current Status and the Next Horizon.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2025Review
- Review
- Characterizing the ADPKD-Kidney international reports · 2025Article
- Metabolic Reprogramming in Autosomal Dominant Polycystic Kidney Disease: Role in Cystogenesis and Novel Therapeutic Approaches.Biomedicines · 2025Review
- Management of Anterior Mediastinal Hodgkin's Lymphoma in Polycystic Kidney Disease: A Case Report.Cureus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic kidney disorder and the fourth leading cause of kidney failure (KF) in adults. Characterized by a reduction in glomerular filtration rate (GFR) and increased kidney size, ADPKD exhibits significant variability in progression, highlighting the urgent need for reliable and predictive biomarkers to optimize management and treatment approaches. This review explores the roles of diverse biomarkers-including clinical, genetic, molecular, and imaging biomarkers-in evaluating disease progression and customizing treatments for ADPKD. Clinical biomarkers such as biological sex, the predicting renal outcome in polycystic kidney disease
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.